International Journal of Original Recent Advanced Research
ISSN (Online): 3048-5479
Vol. 02, Issue 03, May 2025

HEPATOPROTECTIVE AND ANTI-INFLAMMATORY EFFECTS OF MEDICINAL PLANT COMPOUNDS: A COMPREHENSIVE ANALYSIS

Kalyani Pandey[1], Dr. Neelu Jain[2]

Research Scholar, Department of Chemistry, Mansarovar Global University[1]

Professor, Department of Chemistry, Mansarovar Global University[2]

ABSTRACT

The liver metabolises most xenobiotics that enter the body, and that same catalytic burden makes it uniquely vulnerable to drug overdose, viral hepatitis, sustained alcohol intake and the metabolic strain of fatty-liver disease. Approved pharmacological options remain thin. N-acetylcysteine rescues paracetamol overdose, yet little else in the conventional formulary directly shields the hepatocyte. Against this gap, a defined group of plant secondary metabolites has been examined for decades: silymarin from milk thistle, curcumin from turmeric, andrographolide, glycyrrhizin, picroliv, phyllanthin and the boswellic acids, among others. What unites chemically unrelated molecules is a shared mechanistic signature. They quench oxidative stress by restoring reduced glutathione and the antioxidant enzyme battery while activating Nrf2/ARE signalling; they suppress NF-κB-driven transcription of TNF-α, IL-1β, IL-6, COX-2 and iNOS; and several blunt TGF-β1/Smad fibrogenesis. This analysis draws together experimental and clinical findings across the principal compounds, maps their overlapping molecular targets, and weighs the persistent translational obstacles — poor oral bioavailability, inconsistent standardisation, and a shortage of adequately powered trials. Multi-target phytoconstituents emerge as credible hepatoprotective adjuncts, though their promise still outruns the quality of the human evidence.

Keywords: *Hepatoprotection[1], Silymarin[2], Curcumin[3], Oxidative Stress[4], NF-κB Signalling[5], Anti-inflammatory Phytochemicals[6].*

1. INTRODUCTION

Roughly 1.5 to 2 million deaths each year are attributed to liver disease worldwide, a figure that has drifted upward as metabolic dysfunction-associated steatotic liver disease has spread alongside obesity and type 2 diabetes. The organ sits at a metabolic crossroads. Nutrients, hormones and toxins arriving through the portal vein are processed by hepatocytes whose dense complement of cytochrome P450 enzymes both detoxifies and, paradoxically, bioactivates. Carbon tetrachloride becomes the trichloromethyl radical; paracetamol is converted to the reactive quinone-imine NAPQI. When these reactive species outpace cellular defences, the sequence that follows is familiar glutathione depletion, lipid peroxidation, mitochondrial failure, and the recruitment of an inflammatory infiltrate that amplifies the initial insult.

Conventional hepatology has surprisingly little to offer at the cellular level. Antiviral agents control hepatitis B and cure hepatitis C; corticosteroids help in autoimmune and severe alcoholic hepatitis. Beyond N-acetylcysteine for paracetamol toxicity, though, no widely licensed drug directly protects hepatocytes across the spectrum of injury. That vacancy explains the long-standing clinical interest in botanical remedies, many of which entered use through Ayurveda, traditional Chinese medicine and European folk practice centuries before their active principles were isolated. This review consolidates the mechanistic and clinical literature on the best-characterised hepatoprotective phytoconstituents. Rather than cataloguing every plant claimed to benefit the liver — a list running to several hundred species the focus falls on compounds with defined chemistry, reproducible pharmacology and, where available, human data. Three questions organise the analysis. Which molecular pathways do these compounds actually engage? How consistent is the evidence for enzyme normalisation and cytokine suppression? And what stands between promising preclinical activity and reliable therapeutic use?

2. LITERATURE REVIEW

The scientific study of plant hepatoprotectants matured through three overlapping phases: ethnopharmacological documentation, isolation of active constituents, and mechanistic dissection. Madrigal-Santillán et al. (2014) surveyed the field broadly, cataloguing natural products with demonstrable hepatoprotective activity and grouping them by antioxidant, anti-inflammatory and antifibrotic behaviour. Their synthesis underscored a recurring theme that most effective agents act at more than one node of the injury cascade rather than through a single receptor. Silymarin has attracted the densest literature. Saller, Meier and Brignoli (2001) reviewed its clinical application in liver disease and noted membrane-stabilising and antioxidant actions, while acknowledging heterogeneous trial quality. Later, Abenavoli et al. (2018) revisited milk thistle chemistry and its nutraceutical positioning, and Federico, Dallio and Loguercio (2017) argued that the silibinin fraction underpins most of the observed benefit. The picture that emerges is of a compound with a coherent mechanism but an uneven clinical record, partly because early studies used poorly bioavailable formulations. Curcumin research followed a different arc. Aggarwal and Harikumar (2009) positioned it as a broad anti-inflammatory agent acting largely through NF-κB suppression, and Gupta, Patchva and Aggarwal (2013) distilled lessons from dozens of clinical trials chief among them the crippling limitation of oral bioavailability. Domitrović and Potočnjak (2016) provided perhaps the most systematic mechanistic overview of hepatoprotective natural compounds, linking specific structural classes to defined signalling outcomes. Girish and Pradhan (2012), working with a carbon-tetrachloride model, compared picroliv, curcumin and ellagic acid directly against silymarin, offering a rare head-to-head reference point. Across these works a consensus holds: oxidative stress and NF-κB inflammation are the two levers these compounds pull hardest, and bioavailability is the recurring obstacle to translation.

3. METHODOLOGY

This is an integrative narrative review rather than a formal meta-analysis. Peer-reviewed literature was retrieved from PubMed, Scopus and ScienceDirect using combinations of the terms hepatoprotective, anti-inflammatory, silymarin, curcumin, andrographolide, glycyrrhizin, oxidative stress and NF-κB, with attention to primary pharmacological studies, mechanistic investigations and clinical trials published up to 2025. Preference was

given to work reporting defined active constituents and quantifiable endpoints serum transaminases, tissue antioxidant status, cytokine concentrations, or histological scoring. Quantitative values presented in the figures and tables that follow are representative syntheses pooled across comparable experimental models to illustrate relative magnitude and direction of effect. They are offered as an integrative overview, not as pooled effect sizes from a systematic statistical meta-analysis; primary sources should be consulted for exact study-level data. Where clinical evidence exists, it is reported separately from animal findings, since the two rarely align cleanly.

4. PRINCIPAL HEPATOPROTECTIVE PHYTOCONSTITUENTS AND BOTANICAL SOURCES

The compounds examined here span several chemical classes flavonolignans, diarylheptanoids, diterpenoid lactones, triterpenoid saponins and lignans yet converge on similar biological outcomes. Table 1 summarises the principal agents, their botanical origin, chemical family and dominant reported mechanism.

Table 1: Principal hepatoprotective phytoconstituents, botanical source and dominant mechanism

Compound	Botanical source	Chemical class	Dominant reported mechanism
Silymarin / silibinin	Silybum marianum (milk thistle)	Flavonolignan	Antioxidant; membrane stabilisation; protein synthesis
Curcumin	Curcuma longa (turmeric)	Diarylheptanoid	NF-κB inhibition; Nrf2 activation
Andrographolide	Andrographis paniculata	Diterpenoid lactone	NF-κB and iNOS suppression; antioxidant
Glycyrrhizin	Glycyrrhiza glabra (licorice)	Triterpenoid saponin	Anti-inflammatory; membrane protection; antiviral
Picroliv	Picrorhiza kurroa	Iridoid glycoside mixture	Antioxidant; bile-flow restoration
Phyllanthin	Phyllanthus amarus / niruri	Lignan	Antioxidant; anti-HBV activity
Wedelolactone	Eclipta alba (bhringraj)	Coumestan	Antioxidant; anti-fibrotic
Boswellic acids	Boswellia serrata	Pentacyclic triterpene	5-LOX inhibition; anti-inflammatory
Baicalin	Scutellaria baicalensis	Flavone glycoside	NF-κB suppression; antioxidant
Berberine	Berberis / Coptis spp.	Isoquinoline alkaloid	AMPK activation; anti-inflammatory

Source: compiled from Madrigal-Santillán et al. (2014); Domitrović & Potočnjak (2016); Stickel & Schuppan (2007).

Silymarin, a mixture dominated by silibinin (silybin), remains the reference agent against which others are frequently benchmarked. Curcumin and glycyrrhizin have the strongest clinical footprints the latter used for decades in Japan as the intravenous preparation Stronger Neo-Minophagen C. Andrographolide and phyllanthin

carry additional antiviral interest, while boswellic acids stand out for a distinct pharmacology centred on 5-lipoxygenase rather than the cyclooxygenase–NF-κB axis.

5. MECHANISMS OF HEPATOPROTECTION

Hepatic injury, whatever its trigger, funnels through a small number of shared pathways. Understanding where each phytoconstituent intervenes clarifies both their utility and their limits. Figure 1 maps the convergent cascade and the nodes at which plant compounds act.



Figure 1. Convergent pathways of hepatic injury and phytochemical intervention nodes.

5.1 OXIDATIVE STRESS AND ANTIOXIDANT DEFENCE

Reactive oxygen species are the common currency of hepatotoxicity. Li et al. (2015) reviewed the central place of oxidative stress across liver diseases, and it is precisely here that most phytoconstituents earn their reputation. Silymarin and curcumin directly scavenge free radicals, but their more durable contribution is upstream: activation of nuclear factor erythroid 2-related factor 2 (Nrf2), which drives transcription of glutathione-synthesising enzymes, superoxide dismutase, catalase and glutathione peroxidase. Restoring the reduced-glutathione pool is decisive in paracetamol toxicity, where hepatocyte death follows glutathione exhaustion and NAPQI accumulation. Vargas-Mendoza et al. (2014) attributed much of silymarin's benefit to this restoration of endogenous antioxidant capacity rather than to direct scavenging alone.

5.2 MEMBRANE STABILISATION AND CYP450 MODULATION

Silymarin alters hepatocyte membrane permeability, limiting the entry of toxins and the leakage of cytosolic enzymes the mechanistic basis for the fall in serum transaminases seen across models. Several compounds also modulate cytochrome P450 activity, and this cuts both ways. Down-regulating CYP2E1 reduces the bioactivation of carbon tetrachloride and ethanol, a protective effect; but the same enzyme inhibition underlies clinically relevant herb–drug interactions discussed later.

International Journal of Original Recent Advanced Research
ISSN (Online): 3048-5479
Vol. 02, Issue 03, May 2025

5.3 ANTI-APOPTOTIC AND ANTI-FIBROTIC ACTIONS

Beyond blunting the initial insult, hepatoprotective compounds influence how injured cells decide to live or die. Curcumin and silibinin shift the Bcl-2/Bax balance toward survival and limit caspase activation. At the fibrotic end of the spectrum, hepatic stellate cells are the key effector; once activated they deposit collagen under TGF-β1/Smad signalling. Andrographolide, wedelolactone and silymarin have each been reported to suppress stellate-cell activation and TGF-β1 expression, slowing the drift from reversible injury toward established fibrosis. Figure 2 shows the resulting normalisation of serum transaminases across the leading compounds.



Figure 2. Attenuation of serum ALT and AST by principal phytoconstituents (representative pooled values).

Table 2: Reported modulation of hepatic biochemical and oxidative markers (representative direction of effect)

Marker	CCl_4 model	APAP model	Ethanol model	Direction sought
ALT / AST (serum)	↓↓	↓↓	↓	Decrease
Alkaline phosphatase	↓	↓	↓	Decrease
Total bilirubin	↓	↓	–	Decrease
Malondialdehyde (MDA)	↓↓	↓↓	↓↓	Decrease
Reduced glutathione (GSH)	↑↑	↑↑	↑	Increase
SOD / catalase	↑	↑	↑	Increase

Source: synthesised from Girish & Pradhan (2012); Domitrović & Potočnjak (2016); Li et al. (2015). ↓ decrease, ↑ increase, – minimal/variable.

6. ANTI-INFLAMMATORY MECHANISMS AND MOLECULAR TARGETS

Inflammation is not a bystander in liver injury it drives progression. Kupffer cells, the resident macrophages, sense damage-associated signals and release a cytokine cascade that recruits further immune cells and sustains

hepatocyte stress. The anti-inflammatory activity of these compounds is therefore not incidental to hepatoprotection; it is central to it.

The nuclear factor-κB pathway is the dominant target. Under resting conditions NF-κB is sequestered by inhibitory IκB proteins; inflammatory stimuli trigger IκB degradation and NF-κB translocation to the nucleus, where it transcribes TNF-α, IL-1β, IL-6, COX-2 and iNOS. Curcumin, andrographolide, baicalin and silymarin each interrupt this sequence, most commonly by preventing IκB degradation. Boswellic acids follow a separate route — selective inhibition of 5-lipoxygenase, curbing leukotriene synthesis, as Ammon (2016) detailed. Figure 3 arranges the reported suppression of individual mediators across compounds, and the boswellic-acid signature at 5-LOX stands out clearly against the NF-κB-centred profile of the others.



Figure 3. Reported down-regulation of inflammatory mediators by selected phytocompounds.

A further layer involves the NLRP3 inflammasome, which processes pro-IL-1β into its active form. Curcumin and berberine have been reported to dampen inflammasome assembly, adding to their cytokine-suppressing effect. Table 3 sets out the principal molecular targets and the functional consequence of engaging each.

Table 3: Molecular targets of anti-inflammatory phytoconstituents and functional consequences

Target	Representative compounds	Functional consequence
NF-κB (IκB kinase)	Curcumin, andrographolide, baicalin, silymarin	Reduced TNF-α, IL-1β, IL-6 transcription
COX-2	Curcumin, andrographolide	Lower prostaglandin-driven inflammation
iNOS	Andrographolide, baicalin	Reduced nitric-oxide-mediated injury
5-Lipoxygenase	Boswellic acids	Suppressed leukotriene synthesis
NLRP3 inflammasome	Curcumin, berberine	Diminished IL-1β maturation
MAPK cascade	Silymarin, curcumin	Modulated stress-kinase signalling

Source: compiled from Aggarwal & Harikumar (2009); Ammon (2016); Domitrović & Potočnjak (2016).

7. EXPERIMENTAL AND CLINICAL EVIDENCE

7.1 PRECLINICAL MODELS

Animal work is remarkably consistent. In carbon-tetrachloride, paracetamol, ethanol, thioacetamide and LPS/D-galactosamine models, the compounds surveyed here reliably lower serum transaminases, restore tissue glutathione and improve histological injury scores. Nagalekshmi et al. (2011) documented andrographolide's protection in a paracetamol model; Girish and Pradhan (2012) benchmarked picroliv and curcumin against silymarin in carbon-tetrachloride toxicity. The reproducibility across laboratories and toxins is genuinely striking and it is exactly this consistency that has sustained clinical interest despite the messier human record.

7.2 CLINICAL EVIDENCE

Human trials tell a more cautious story. Silymarin has been tested most widely; a double-blind randomised trial by Luangchosiri et al. (2015) found it reduced the incidence of antituberculosis drug-induced liver injury, though several earlier trials in alcoholic and viral liver disease produced null or ambiguous results, muddied by variable formulations and dosing. For curcumin in metabolic fatty-liver disease, the systematic review by Mansour-Ghanaei et al. (2019) reported modest but consistent reductions in ALT and AST across randomised trials encouraging, if limited by small samples and short follow-up. Glycyrrhizin has the longest clinical pedigree. Van Rossum et al. (1998) reported ALT reductions in chronic hepatitis C, and Ikeda (2007) observed that long-term glycyrrhizin therapy was associated with a lower incidence of hepatocellular carcinoma in interferon-resistant patients — an intriguing signal, albeit from non-randomised follow-up. Phyllanthus species have been studied for hepatitis B; the Cochrane review by Xia et al. (2011) concluded that the evidence was too weak and heterogeneous to support routine use. Figure 4 contrasts the multi-target profiles of three of the best-studied compounds.



Figure 4. Comparative multi-target activity profile of three representative compounds.

Table 4: Summary of representative clinical evidence

Compound	Clinical context	Reported outcome	Evidence strength
Silymarin	Anti-TB drug-induced injury	Lower incidence of hepatotoxicity	Moderate (RCT)
Curcumin	Metabolic fatty-liver disease	Modest ALT / AST reduction	Low–moderate
Glycyrrhizin	Chronic hepatitis C	ALT reduction; possible HCC-risk signal	Moderate (mixed)
Phyllanthus	Chronic hepatitis B	Inconclusive	Weak / heterogeneous

Source: Luangchosiri et al. (2015); Mansour-Ghanaei et al. (2019); van Rossum et al. (1998); Ikeda (2007); Xia et al. (2011).

8. DISCUSSION

If the pharmacology is so favourable, why have these compounds not displaced conventional care? The honest answer is that biology and pharmaceutics diverge. Curcumin is the clearest example — potent in the dish, yet so poorly absorbed and so rapidly metabolised that unmodified oral doses barely register in plasma. Phytosome complexes, nanoparticle carriers and co-administration with piperine improve exposure considerably, but the formulations used in the strongest preclinical studies are often not those tested in patients, which partly explains the gap between laboratory promise and clinical modesty. Standardisation is a second, underappreciated problem. Herbal preparations vary with cultivar, harvest, extraction method and storage; two products bearing the same name may differ severalfold in active content. Without pharmacopoeial control of the constituent responsible for activity, trial results are hard to reproduce and harder to generalise. Safety, often assumed because these are natural products, deserves scrutiny too. Glycyrrhizin's mineralocorticoid-like activity can cause pseudoaldosteronism hypertension and hypokalaemia with prolonged use. Silymarin and several others inhibit cytochrome P450 and drug transporters, raising the prospect of clinically meaningful interactions with co-administered medicines. Stickel and Schuppan (2007) cautioned specifically against the assumption that botanical hepatoprotectants are uniformly benign. Salomone, Godos and Zelber-Sagi (2016) framed the realistic position well: natural antioxidants are plausible adjuncts in fatty-liver disease, but the evidence base needs the discipline of large, well-designed trials before firm recommendations are possible.

9. CONCLUSION

A coherent picture emerges from the accumulated evidence. Hepatoprotective plant compounds work not through a single elegant mechanism but by acting simultaneously on the two engines of liver injury — oxidative stress and inflammation with several extending their reach to apoptosis and fibrosis. That multi-target character is their real strength and, arguably, an advantage over single-pathway synthetic drugs in a disease process as networked as hepatic injury. Yet enthusiasm must be tempered. The preclinical case is strong and consistent; the clinical case is patchy, held back by bioavailability, poor standardisation and a shortage of rigorous trials. The path forward is not fresh discovery so much as disciplined development pharmacokinetic optimisation, standardised and characterised preparations, and adequately powered randomised trials with hard endpoints. Silymarin, curcumin and glycyrrhizin are the most credible candidates to carry that work. Treated as serious

pharmacological agents rather than gentle tonics, this class of compounds may yet fill part of the therapeutic vacancy that has defined hepatology's relationship with liver-cell protection.

10. REFERENCES

1. Abenavoli, L., Izzo, A. A., Milić, N., Cicala, C., Santini, A., & Capasso, R. (2018). Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. Phytotherapy Research, 32(11), 2202–2213. https://doi.org/10.1002/ptr.6171

2. Aggarwal, B. B., & Harikumar, K. B. (2009). Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. International Journal of Biochemistry & Cell Biology, 41(1), 40–59. https://doi.org/10.1016/j.biocel.2008.06.010

3. Ammon, H. P. T. (2016). Boswellic acids and their role in chronic inflammatory diseases. Advances in Experimental Medicine and Biology, 928, 291–327. https://doi.org/10.1007/978-3-319-41334-1_13

4. Domitrović, R., & Potočnjak, I. (2016). A comprehensive overview of hepatoprotective natural compounds: Mechanism of action and clinical perspectives. Archives of Toxicology, 90(1), 39–79. https://doi.org/10.1007/s00204-015-1580-z

5. Federico, A., Dallio, M., & Loguercio, C. (2017). Silymarin/silybin and chronic liver disease: A marriage of many years. Molecules, 22(2), 191. https://doi.org/10.3390/molecules22020191

6. Girish, C., & Pradhan, S. C. (2012). Hepatoprotective activities of picroliv, curcumin, and ellagic acid compared to silymarin on carbon-tetrachloride-induced liver toxicity in mice. Journal of Pharmacology and Pharmacotherapeutics, 3(2), 149–155. https://doi.org/10.4103/0976-500X.95515

7. Gupta, S. C., Patchva, S., & Aggarwal, B. B. (2013). Therapeutic roles of curcumin: Lessons learned from clinical trials. The AAPS Journal, 15(1), 195–218. https://doi.org/10.1208/s12248-012-9432-8

8. Ikeda, K. (2007). Glycyrrhizin injection therapy prevents hepatocellular carcinogenesis in patients with interferon-resistant active chronic hepatitis C. Hepatology Research, 37(s2), S287–S293. https://doi.org/10.1111/j.1872-034X.2007.00199.x

9. Li, S., Tan, H. Y., Wang, N., Zhang, Z. J., Lao, L., Wong, C. W., & Feng, Y. (2015). The role of oxidative stress and antioxidants in liver diseases. International Journal of Molecular Sciences, 16(11), 26087–26124. https://doi.org/10.3390/ijms161125942

10. Luangchosiri, C., Thakkinstian, A., Chitphuk, S., Stitchantrakul, W., Petraksa, S., & Sobhonslidsuk, A. (2015). A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury. BMC Complementary and Alternative Medicine, 15, 334. https://doi.org/10.1186/s12906-015-0861-7

11. Madrigal-Santillán, E., Madrigal-Bujaidar, E., Álvarez-González, I., Sumaya-Martínez, M. T., Gutiérrez-Salinas, J., Bautista, M., … Morales-González, J. A. (2014). Review of natural products with hepatoprotective effects. World Journal of Gastroenterology, 20(40), 14787–14804. https://doi.org/10.3748/wjg.v20.i40.14787

12. Mansour-Ghanaei, F., Pourmasoumi, M., Hadi, A., & Joukar, F. (2019). Efficacy of curcumin/turmeric on liver enzymes in patients with non-alcoholic fatty liver disease: A systematic review of randomized controlled trials. Integrative Medicine Research, 8(1), 57–61. https://doi.org/10.1016/j.imr.2018.07.004

13. Nagalekshmi, R., Menon, A., Chandrasekharan, D. K., & Nair, C. K. K. (2011). Hepatoprotective activity of Andrographis paniculata and Swertia chirayita. Food and Chemical Toxicology, 49(12), 3367–3373. https://doi.org/10.1016/j.fct.2011.09.026

14. Saller, R., Meier, R., & Brignoli, R. (2001). The use of silymarin in the treatment of liver diseases. Drugs, 61(14), 2035–2063. https://doi.org/10.2165/00003495-200161140-00003

15. Salomone, F., Godos, J., & Zelber-Sagi, S. (2016). Natural antioxidants for non-alcoholic fatty liver disease: Molecular targets and clinical perspectives. Liver International, 36(1), 5–20. https://doi.org/10.1111/liv.12975

16. Stickel, F., & Schuppan, D. (2007). Herbal medicine in the treatment of liver diseases. Digestive and Liver Disease, 39(4), 293–304. https://doi.org/10.1016/j.dld.2006.11.004

17. Vargas-Mendoza, N., Madrigal-Santillán, E., Morales-González, Á., Esquivel-Soto, J., Esquivel-Chirino, C., García-Luna y González-Rubio, M., … Morales-González, J. A. (2014). Hepatoprotective effect of silymarin. World Journal of Hepatology, 6(3), 144–149. https://doi.org/10.4254/wjh.v6.i3.144

18. van Rossum, T. G., Vulto, A. G., de Man, R. A., Brouwer, J. T., & Schalm, S. W. (1998). Glycyrrhizin as a potential treatment for chronic hepatitis C. Alimentary Pharmacology & Therapeutics, 12(3), 199–205. https://doi.org/10.1046/j.1365-2036.1998.00309.x

19. Xia, Y., Luo, H., Liu, J. P., & Gluud, C. (2011). Phyllanthus species for chronic hepatitis B virus infection. Cochrane Database of Systematic Reviews, (4), CD008960. https://doi.org/10.1002/14651858.CD008960.pub2

20. Zhang, A., Sun, H., & Wang, X. (2013). Recent advances in natural products from plants for treatment of liver diseases. European Journal of Medicinal Chemistry, 63, 570–577. https://doi.org/10.1016/j.ejmech.2012.12.062